Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. (IBRX)’s ANKTIVA Following QUILT Data

Company Overview - ImmunityBio, Inc. is a U.S. biotechnology company focused on developing next-generation immunotherapies and vaccines aimed at enhancing the natural immune system to combat cancers and infectious diseases [4] Financial Performance - Piper Sandler raised its price target on ImmunityBio, Inc. (IBRX) to $7 from $5, maintaining an Overweight rating [2] - U.S. ANKTIVA net sales surged by nearly 700% year over year, reaching $113 million in 2025, with projected revenue of $180 million in 2026 [2] Clinical Developments - ImmunityBio reported Phase 2 QUILT-3.078 results for recurrent GBM, showing that the longest survival was 12 months, with 19 out of 23 patients still alive [3] - The regimen demonstrated a reasonable safety profile, with preserved immunological competence and improved severe lymphopenia (ALC ≥1.4 ×10³/µL) [3] Future Prospects - There is potential for label expansion for ANKTIVA in 2027, contingent on positive data from the upcoming QUILT-2.005 study expected in Q4 2026 [2][3]